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The Abstract 
 
Purpose: To assess enhanced depth imaging spectral-domain optical coherence 
tomography (EDI-SDOCT) findings in patients with Vogt-Koyanagi-Harada (VKH) 
disease, comparing to a normal population sample. 
Methods: A retrospective review was performed using 18 eyes of 9 VKH patients and 
18 eyes of 9 normal subjects who performed EDI-SDOCT. Choroidal thickness (CT) 
was manually measured on a 7-horizontal-raster scan centered on the fovea. 
Measurements on the fovea and 500, 1500 e 3000 m from the fovea to the nasal and 
temporal side were registered. A total of 49 points were measured on each sample and 
grouped into quadrants: nasal-superior (NS), nasal-inferior (NI), temporal-superior (TS) 
and temporal-inferior (TI). Central retinal macular thickness (CRMT) and retinal 
macular volume (RMV) were determined. CT, CRMT, RMV were correlated with 
disease duration. 
Results: The mean subfoveal choroidal thickness (F) in the convalescent stage was 312 
µm (SD 130) and 394 µm (SD 97) in the control group (p=0.055). At 1500 and 3000 
µm temporal to the fovea (T15 and T30) the choroid presented significantly thinner in 
the patients group (p=0.019 and p=0.047). Significant differences were also found in 
NS, TS and TI quadrants, (p=0.044, p=0.022, p=0.034), were the choroid showed to be 
thinner. Correlations between CT, CRMT, RMV and disease duration were not 
significant (p=0.469, p=0.706, p=0.915).  
Conclusions: VKH patients presented thinner choroids in the convalescent stage, 
compared with normal subjects. This difference is more evident in the temporal 
quadrant. Choroidal evaluation in VKH patients with EDI-SDOCT seems to be helpful 
in monitoring the disease status. 
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Introduction 
Vogt-Koyanagi-Harada (VKH) syndrome is a rare multisystem autoimmune 
granulomatous inflammatory disorder involving the eyes, inner ear, skin and meninges 
(Yanoff &  Duker 2004; Pan &  Hirose 2011). Clinically these patients may present 
with posterior uveitis with some extra-ocular findings as meningismus and 
cerebrospinal fluid pleocytosis, tinnitus, perception deafness, alopecia, vitiligo and 
poliosis. 
The disease appears more frequently among Asians, Indians and Latin Americans. 
Females also have a higher probability of developing the disease, especially in their 
fourth to fifth decades (Yanoff &  Duker 2004). 
Ocular findings in VKH disease are bilateral panuveitis with multifocal serous retinal 
detachments (Read et al. 2001; Rao 2007; Pan &  Hirose 2011). The foremost site of 
inflammation is the choroid. It begins with an autoimmune reaction against stromal 
choroidal melanocytes proteins secondarily affecting retinal pigment epithelium (RPE) 
and the retina (Moorthy et al. 1995; Damico et al. 2005; Sugita et al. 2006). 
VKH syndrome is clinically divided into four stages (Read et al. 2001; Yanoff &  Duker 
2004; Pan &  Hirose 2011). The prodromal stage is characterized by systemic, mostly 
neurological manifestations. The uveitic stage consists in an anterior and/or posterior 
bilateral uveitis, with hyperemia and swelling of the optic disc. It also includes focal 
areas of subretinal fluid or bullous serous retinal detachments. In the convalescent stage 
the eyes may display choroidal depigmentation (sunset glow fundus), alterations of the 
retinal pigment epithelium (RPE) with foci or lines of hyperpigmentation and nummular 
areas of chorioretinal atrophy, peripheral yellow-white lesions (Dalen-Fuchs nodules) 
and perilimbal vitiligo (Sugiura’s sign). A chronic recurrent stage may present as acute 
iridociclitis accompanied by iris nodules and mutton-fat keratic precipitates. Other 
manifestations and complications, such as choroidal neovascularization, posterior 
subcapsular cataract, glaucoma and posterior synechiae, may occur at this phase.  
In VKH syndrome, corticosteroids are the treatment keystone. Other therapy schemes 
contemplate immunosuppressive or biologic agents and anti-vascular endothelial 
growth factors (anti-VEGFs) (Bordaberry 2010). 
Diagnosis is based on clinical presentation and ophthalmologic imaging modalities such 
as B-mode ultrasonographic imaging, fluorescein angiography (FFA), indocyanine 
green angiography (ICGA) and optical coherence tomography (OCT) (Bouchenaki &  
Herbort 2001; Wylęgała et al. 2008; Bordaberry 2010).  
Histopathologic studies (Perry &  Font 1977; Inomata &  Sakamoto 1990) have shown 
that lymphocytic infiltration is responsible to choroidal thickening in VKH disease. 
However, insufficient data concerning the choroid biomorphologic changes during the 
course of the disease is available. In vivo observation and monitoring of the ocular 
structure most affected by VKH could be crucial in a clearer understanding of its 
pathophysiology and monitoring of its treatment efficacy. 
OCT is a non-invasive imaging method that enables cross sectional-images of the retina 
and the RPE (Wylęgała et al. 2008; Regatieri et al. 2012), allowing the acquisition of 
morphologic parameters and morphometric measurements, especially spectral-domain 
OCT (SDOCT). 
Recently, Spaide et al (Spaide et al. 2008) described a technique called “enhanced depth 
imaging” (EDI), in order to solve this difficulty. This technique improves the view of 
the choroid, from Bruch membrane to the suprachoroidal space and sharper the tissue 
particularities. It also provides choroidal thickness (CT) measurements and the 
observation of choroidal abnormalities. 
The aim of this study is to assess EDI-SDOCT findings in patients with VKH disease 
comparing to a normal population group. Differences between acute and chronic stage 
findings were also analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
Subjects 
A retrospective review was performed based on clinical records of 9 patients (18 eyes) 
with the diagnosis of Vogt-Koyanagi-Harada (VKH) disease, followed in the 
Department of Ophthalmology of S. João Hospital Center, in Porto. 
Inclusion criteria were patients with VKH disease respecting the revised diagnostic 
criteria of VKH disease, established by an international committee on nomenclature 
(Read et al. 2001), who were submitted to spectral-domain optical coherence 
tomography (SDOCT) examination.  
None of the patients presented confounding simultaneous conditions such as history of 
ocular trauma or surgery, lymphoma, posterior scleritis, central serous 
chorioretinopathy, acute posterior multifocal placoid pigment epitheliopathy, idiopathic 
uveal effusion syndrome, ocular sarcoidosis, tuberculosis or lupus. Only 3 eyes of 2 
patients had a refractive error superior to 5 diopters.   
Demographic and clinical data including age, sex, ethnicity, best corrected visual acuity 
(BCVA), neurologic/auditory or integumentary findings, disease duration, treatment 
performed, slit-lamp biomicroscopy and indirect ophthalmoscopy description were 
collected. Information from retinal and choroidal morphological SDOCT findings was 
registered. Data on fluorescein and indocyanine green angiography findings was also 
registered.  
Age and sex- matched healthy subjects with a refractive error of less than 4 diopters 
from a database of our Ophthalmology Department, who had been examined with a 
SDOCT, were used as controls. 
Ethical approval was obtained from the S. João Hospital Center Ethics Committee for 
Health, and the Administrative Council and Local Office of Research from S. João 
Hospital Center, Porto. The tenets of Declaration of Helsinki were respected. 
 
SD OCT imaging and analysis 
The SDOCT images were acquired using the Heidelberg Spectralis OCT system 
(Heidelberg Engineering, Heidelberg, Germany), and an enhanced depth imaging (EDI) 
acquisition mode was also used to visualize the choroid.  
The retinal analysis included a three-dimensional OCT volume generated by a 19-
section raster scan with 512 voxels per depth-scan (A-scan), across a 20x15º field 
centred on the fovea. A 6-mm high quality horizontal and vertical scan 30º through the 
fovea, with 768 voxels per A-scan was also used. Retinal thickness and volume 
measurements were performed using the system software automatic analysis. For 
choroidal imaging both the high definition lines as well as the 19-section raster scan 
were used in the EDI mode, using the follow-up tool for setting reference in order to 
obtain a perfect alignment between retina and choroid in every examination. Manual 
segmentation of the choroidal layer was performed dragging the reference line from the 
retinal boundary (internal limiting membrane) to the choroidal-scleral interface in each 
of the scans (Fig. 1). This manual segmentation of the choroidal boundary was reviewed 
by an ophthalmologist, experienced in operating an OCT device. Choroidal thickness 
(CT) was measured at the fovea (F) and at 500 m, 1500 m and 3000 m intervals 
nasal (N5, N15, N30, respectively) and temporal (T5, T15, T30, respectively) to the 
fovea, through the entire field. In order to facilitate the graphic representation only the 
measurements in 7 of the 19 sections, one centred on the fovea and the others distanced 
by 740 m from each other, were displayed. A total of 49 CT measurements were 
registered on both samples, and grouped into quadrants: nasal-superior (NS), nasal-
inferior (NI), temporal-superior (TS) and temporal-inferior (TI). 
 
Statistical Analysis 
Statistical analysis was performed using the SPSS software version 20.0. Nonparametric 
tests were used: Mann-Whitney U test, Wilcoxon rank-test and Spearman’s rank 
correlation test. A 95% confidence interval and a 5% level of significance were adopted; 
therefore, the results with a p-value <0.05 were considered significant. 
 
 
 
 
 
 
 
 
 
 
Results 
Eighteen eyes of 9 patients with VKH, with a M/F ratio of 2:7 and a mean age of 47.1 
years (SD 9.5), ranging from 36 to 71 years. Eighteen eyes of 9 normal subjects with a 
M/F ratio of 1:8 and a mean age of 49.0 years (SD 6.2) were used as controls. There 
was no significant difference in the mean age between these two groups (p=0.152, 
Mann-Whitney U test). Both samples were predominantly female patients, with a total 
of 30 eyes of 15 women (83.3%) and 6 eyes of 3 men (16.7%). 
Altogether, 4 out of 9 patients had neurological findings in the acute stage and 3 
patients presented integumentary findings after onset of central nervous system or 
ocular disease.  
Two patients were classified as presenting a complete diagnosis of VKH disease, 
according to the revised diagnostic criteria (Read et al. 2001). Five had an incomplete 
diagnosis and two a probable diagnosis. 
The follow-up period since the diagnosis ranged from 7 to 600 months (0.58 to 50 
years). The mean duration was 123 months (SD 181) and the median was 72 months.  
All 9 patients were submitted to systemic corticotherapy in the acute phase. Five of 
these patients required another immunossupressive agent to control the inflammation. 
Two patients presented bilateral recurrent disease. All the 18 eyes presented a sunset 
glow fundus in the convalescente phase. A total of 8 eyes of 4 patients presented ocular 
hypertension (OHT) during the follow-up period, requiring topical hypotensive 
medication. None of these patients required glaucoma surgery. 
Characteristics of the study groups are depicted in table 1. 
BCVA in the acute stage ranged from 20/200 to 20/25 (logarithmic of the minimum 
angle of resolution [logMAR] ranging from 1.00 to 0.1) and a median logMAR 0.4. 
BCVA in the convalescent stage was between < 20/200 and 20/16 (logMAR ranging 
from 3.00 to -1.0), with a median logMAR of 0.0. We found statistically significant 
difference (p=0.002, Wilcoxon rank-test) between acute and convalescent BCVA. 
In the acute stage of disease, the mean central retinal macular thickness (CRMT), 
measured in the 1mm-diameter central ring was 673 µm (SD 186). The mean CRMT in 
controls was 279 µm (SD 16). The difference between median CRMT in acute stage 
patients and controls was statistically significant (p<0.0001, Mann-Whitney U test). The 
retinal macular volume (RMV) in the 6mm diameter ring in acute stage patients (mean 
12.6 mm
3
; SD 1.9) was also increased compared to controls (mean 8.7 mm
3
; SD 0.4) 
(p<0.0001). 
In the convalescent stage the mean CRMT decreased to 282 µm (SD 28) and VRM to 
8.3 mm
3 
(SD 1.5). When analyzing the same parameters in the convalescent phase, no 
differences were found in the CRMT (p=0.888, Mann-Whitney U test) and RMV 
(p=0.628) between the patient’s group and controls. 
However, the CRMT significantly decrease from the acute to the convalescent stage 
(p=0.012, Wilcoxon rank-test). Those differences were also found in the RMV 
(p=0.012). 
The time of follow-up was not significantly correlated to CRMT (p=0.706, Spearman’s 
correlation test) (Fig. 2) or RMV (p=0.915) in the convalescent stage. 
None of the patients had an EDI-SDOCT evaluation of the choroid in the acute stage of 
disease, so there is no data concerning the CT in this phase. On the other hand, in the 
convalescent stage, the mean CT measured in the fovea (F) was 312 µm (SD 130), 
ranging from 49 to 551 µm. The mean CT in controls was 394 µm (SD 97), ranging 
from 221 to 580 µm. Differences weren’t significant the patient’s group and controls 
(p=0.055, Mann-Whitney U test). 
Analyzing an horizontal scan crossing the fovea it is possible to verify that CT 
diminishes from the fovea to either nasal and temporal sides in both samples (Fig. 3).  
Furthermore, measurements performed at 1500 and 3000 µm temporal to the fovea (T15 
and T30, respectively) were significantly thinner in patients compared to controls, 
(p=0.019 and p=0.047, respectively, Mann-Whitney U test). The other measurements 
were closely statistically significant (N30 p=0.068; N5 p=0.059; F p=0.055; T5 
p=0.051), except N15 (p=0.091). Overall, while analyzing the CT by quadrants, it was 
thinner in patients compared to controls in all the quadrants (Fig. 4). A statistically 
significant difference was found in NS, TS and TI quadrants (p=0.044, p=0.022, 
p=0.034, respectively). NI quadrant measurements weren’t significantly different 
(p=0.118). 
Correlation between subfoveal choroidal thickness (F) and follow-up period was not 
statistically significant (p=0.469, Spearman’s correlation test), nevertheless there seems 
to be some negative correlation (Fig.5).  
No significant correlation between either foveal retinal thickness or subfoveal choroidal 
thickness (F) and BCVA was found (p=0.467 and p=0,275, respectively) in the 
convalescent phase. 
The treatment plan choice, either using corticosteroids or corticosteroids combined with 
other immunosuppressive agent, did not correlate to the subfoveal choroidal 
thickness (p=1.000, Mann-Whitney U test).  
Considering ocular pressure, no significant differences were found in CT by quadrants 
between patients diagnosed with ocular hypertension (OHT) and those with no such 
history (NS p=0.122; TS p=0.173; NI p=0.274; TI p=0.360, Mann-Whitney U test). 
However, the choroid tends to be thicker among patients with OHT at all the macular 
quadrants compared to the other patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Considering that VKH disease begins as an autoimmune reaction against stromal 
choroidal melanocytes proteins, secondarily affecting the RPE and the retina (Moorthy 
et al. 1995; Damico et al. 2005; Sugita et al. 2006), it is crucial to be recognized the 
importance of studying choroidal morphology throughout the disease. However, the 
RPE was a highly limiting factor in imaging the underlying choroids, due to its pigment 
density. Enhanced depth imaging modalities, using spectral-domain OCT, solved these 
difficulties, allowing imaging beyond the RPE. EDI-SDOCT is proving to be one of the 
most useful tools for choroidal morphologic evaluation (Spaide et al. 2008; Ishihara et 
al. 2009; Fong et al. 2011). 
Previous studies showed the increase of CT in the active stage of the disease (Fong et al. 
2011; Maruko et al. 2011). Unfortunately, due to the retrospective nature of this study, 
we didn’t have any imaging of the choroid using EDI technique in the acute stage, 
precluding the comparison between choroidal measurements in acute versus 
convalescent stage. Only retinal measurements were obtained from the optical scans 
available in acute stages. A total of 4 VKH patients (8 eyes) performed SDOCT during 
the acute stage, repeating this examination while in the chronic stage, this time also 
using the EDI technique. 
This study was also limited by the small size of the sample groups, especially in the 
acute stage.  
Besides that, 3 eyes of VKH patients (16.7%) had a refractive error superior to 5 
diopters which may have contributed to the heterogeneity of our findings. As has been 
studied, ocular axial length influences choroidal thickness (Fujiwara et al. 2009). 
Otherwise, our control sample was very homogeneous, considering that, as already 
stated (Fong et al. 2011), healthy choroidal thickness may vary among study groups as a 
consequence of interracial variety. This sample was also sex and age-matched to the 
patients group. 
We found a significant increase of both CRMT and RMV in the acute stage, compared 
to controls and to the convalescent stage. This finding is easily understandable, 
considering that retinal detachments and retina edema are usually found in the active 
phase of the disease. Similar findings were described by other authors (Yamamoto et al. 
2011). However, neither CRMT nor RMV were significantly different between the 
convalescent stage and the controls, meaning that no relevant macular changes were 
detected in our patients. 
The mean duration of the disease was 123 months (10.3 years) since VKH disease 
diagnosis. Given the small size of our sample, the median appears to be a more reliable 
measure of illness’ duration (median of 72 months). However, our study included 
patients with a wide range of follow-up period. Although previous studies showed a 
negative correlation between CT and duration of disease (Nakai et al. 2012; da Silva et 
al. 2013), with a mean period of disease of 52.5 months and 69 months, respectively, we 
didn’t find a statistically significant correlation. This could be explained by the wide 
range of follow-up periods. We also found no significant correlation in the convalescent 
stage between CRMT and RMV and the duration of the disease. 
In our study we found the urge to measure the choroid not only in the foveal region, or 
along a horizontal scan crossing the fovea, as has been previously done, but also to 
analyze the choroidal profile throughout the all macular area. This is the reason why a 
raster scan choroidal measurement was done. To our knowledge, this has not been done 
so far in VKH patients. 
The median subfoveal choroidal thickness (F) was close to be significantly thinner in 
convalescent VKH patients, compared with controls (p=0.055), although all eyes had 
sunset glow fundus appearence. Another study (Nakai et al. 2012) concluded that 
choroidal thinning seems to be correlated to sunset glow fundus appearance in 
convalescent stage of VKH patients. Despite this, in our study we have demonstrated a 
significant choroidal thinning in NS, TS and TI quadrants in the convalescent stage of 
VKH disease, compared with the control group. The choroid was globally thicker in the 
temporal quadrants (TS and TI) compared to nasal quadrants, as has already been 
described (Ouyang et al. 2011). However, some temporal thinning was found in VKH 
patients, comparing to normal subjects. NI quadrant in the convalescent stage of the 
disease was not significantly thinner compared to controls. It has been demonstrated 
that the choroid is thinner in this inferonasal quadrant in normal subjects (Ouyang et al. 
2011). 
During convalescence, BCVA does not seem to be correlated neither with subfoveal 
choroidal thickness nor with subfoveal retinal thickness. The majority of the patients 
returned to 20/20 BCVA when they became into remission.  
The present study also showed the same distribution of subfoveal choroidal thickness 
despite different treatment options. Early high doses of systemic corticosteroid 
treatment (≥1mg/kg per day) proved to be correlated with better prognostic factors 
(Read et al. 2006; Chee et al. 2009), such as final BCVA. During the acute stage and to 
suppress the choroidal inflammatory levels as soon as possible, most authors 
recommend high dose systemic corticosteroids [e.g. i.v. (pulse) methylprenisolone 
1000mg per day] followed by tapering oral schemes, lessening the probability of 
recurrence (Read et al. 2006; Lai et al. 2009; Bordaberry 2010). According to the 
prognostic factors of VKH disease (Chee et al. 2009) future visual acuity is inversely 
correlated to time of recovering. 
In the current study, 4 patients (8 eyes) presented ocular hypertension during the follow-
up period. We tried to analyse the relationship between the severity of choroidal 
thinning and the presence of this finding. No significant differences were found. Some 
authors (Maul et al. 2011; Mwanza et al. 2011) have already tried to find a correlation 
between glaucoma and choroidal thickness but found no significant results. Once a 
significant percentage of VKH patients develops glaucoma, SDOCT may be a good 
method to study not only the choroid, but also the peripapillary retinal nerve fiber layer. 
Another critique to our study could be made to the method of choroidal measurement. 
Manual segmentation of the choroid is associated with errors and biases, because it is 
subjectively determined by the investigator. Furthermore it is hard to do accurate 
measurements of VKH choroidal outline due to frequent media opacities in VKH 
patients, from cataract or vitreous densifications, often overshadowing the image by 
decreasing the signal strength.  An OCT incorporated software analysis system allowing 
choroidal thickness and volume measurements (similar to the one used to measure 
retinal thickness and volume) may surpass some unavoidable subjectivity. 
Evaluation of the choroidal involvement in VKH patients, using EDI-SDOCT, at the 
moment of the diagnosis, could be helpful for the diagnosis, monitoring the status of the 
disease and assessment of treatment efficacy. EDI-SDOCT has been proved to detect 
low-grade VKH activity (Nakai et al. 2012), therefore quantitative measurement of 
choroidal thickness may be a valuable tool for longitudinal follow-up. We also believe 
that EDI-SDOCT may be a useful monitoring test in VKH treatment while tapering, 
helping to detect recurrence in the convalescent stage. 
In summary objective morphologic evaluation of the choroid seems to be a useful non-
invasive method in the assessment of VKH activity. While trying to map a choroidal 
profile, we found a significant choroidal decrease in the temporal quadrants. Further 
studies could determine if there is a preferential pattern of choroidal map thinning in 
long-standing disease. 
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Figure Legends 
Fig. 1. Manual segmentation of the choroidal layer. A reference line was manually 
positioned in the choroidal-scleral interface in each of the 19 horizontal scans. The 
choroidal thickness profile is represented by the black line in the bottom graphic, where 
we can also see the retinal profile through the same scan. The green vertical line 
crossing the fovea, measures the choroidal thickness in that point (276 µm). CSI- 
choroidal-scleral interface; BM – Bruch’s Membrane 
Fig. 2. Correlation between central retinal macular thickness and follow-up period in 
Vogt-Koyanagi-Harada disease group. Red circles represent individual patients’ eyes 
(p=0.706, Spearman’s correlation test). 
Fig. 3. Graphic showing the mean choroidal thickness measurements in an horizontal 
scan through the fovea (F) and at 500, 1500 and 3000 µm nasal (N500, N1500, N3000) 
and temporal (T500, T1500, T3000) to the fovea. 
Fig. 4. Choroidal thickness measurements by quadrants in Vogt-Koyanagi-Harada 
patients (first image) and controls (second image). TS, NS, TI, NI represent temporal-
superior, nasal-superior, temporal-inferior and nasal-inferior quadrants, respectively. 
Mean values as well as standard deviation and statistic value are described. Mean 
measurements performed through the horizontal scan crossing the fovea at 500, 1500 e 
3000 µm are also displayed.  
Fig. 5. Correlation between central choroidal thickness and follow-up period in Vogt-
Koyanagi-Harada disease group. Red circles represent individual patients’ eyes 
(p=0.469, Spearman’s correlation test) 
 
 
 
 Tables 
Table 1. Demographic and clinical characteristics of controls and patients with Vogt-
Koyanagi-Harada disease. 
Description Controls Patients p-value 
No. individuals (eyes) 9 (18) 9 (18) NA 
Age mean±SD (years) 49.00±6.21 47.11±9.55 0.151 
Male/Female, n 1:8 2:7 0.584 
Disease duration, 
mean±SD 
(range in months) 
NA 123.22±181.37 
(7 to 600) 
NA 
Recurrence NA 2 NA 
Treatment    
-Systemic corticotherapy NA 3 NA 
-Systemic corticotherapy  and 
other immunossupressive agent 
    
NA 
 
5 
 
NA 
-Missings NA 1 NA 
Clinical manifestations 
(acute stage) 
Meningismus NA 3  NA 
Tinnitus NA 3 NA 
Cerebrospinal fluid pleocytosis  NA 3 NA 
Integumentary findings NA 3 NA 
Sunset Glow Fundus in 
convalescent stage (eyes) 
NA 9 (18) NA 
Ocular Hypertension (eyes) NA 4 (8) NA 
NA: non-applicable 
 
 
 
 
 
Illustrations and Graphics 
Fig. 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
50 
100 
150 
200 
250 
300 
350 
400 
N3000 N1500 N500 F T500 T1500 T3000 M
ea
n
 C
h
o
ro
id
a
l 
T
h
ic
k
n
es
s 
(µ
m
) 
Location (µm) 
  
VKH patients Control group 
Fig. 4 
 
 
 
 
 
 
 
 
 
Fig. 5 
 
 
 
 
 
 
 
Anexos 
 
 
 
 
 
 
  
Author Guidelines/Normas da Revista 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Link: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-3768/homepage/ForAuthors.html 
 
Acta Ophthalmologica 
© 2013 Acta Ophthalmologica Scandinavica Foundation 
 
Edited By: Einar Stefánsson 
Impact Factor: 2.629 
ISI Journal Citation Reports © Ranking: 2011: 13/58 (Ophthalmology) 
Online ISSN: 1755-3768 
 
 
 
Author Guidelines 
 
 
Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational 
photo-essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the 
editor, doctoral theses. 
Priority is given to high quality original papers and review articles. Manuscripts are accepted on the 
condition that they have not been, and will not be published elsewhere, except for abstracts of oral 
presentations. All submissions are subject to editorial review and will be reviewed by two or more 
independent reviewers, editorial board members, and guest editors. It is assumed that the author(s) has 
considered the ethical aspects of the study and followed the guidelines of the Helsinki Declaration, which 
should always be specified in the manuscript. 
Online Only Publication 
Letters to the editor are published online only from January 2010, and from January 2010 newly submitted 
letters to the editor will be excempt from colour charges. 
The editor decides wheather any publication is electronic only or both in print and electronic form. The 
authors are notified and consulted on this decision. 
ONLINE SUBMISSION 
Manuscripts to Acta Ophthalmologica should be submitted online via the journal's submission site, 
ScholarOne Manuscripts (formerly known as Manuscript Central). To access this system for submission 
and review, go directly to: 
http://mc.manuscriptcentral.com/acta 
Complete instructions for preparing and submitting manuscripts online are provided at the submission site. 
If you need assistance, please contact our support staff by phone at +1 434 817 2040 ext. 167 or via e-
mail at support@scholarone.com 
Please note that docx files are compatible with the journal submission systems. 
ORIGINAL PAPERS 
Arrangement of the manuscript: The manuscript should include the following: 1) title page; 2) abstract, 
and key words; 3) main text (introduction, materials and methods, results, discussion); 4) 
acknowledgement; 5) references; 6) figure and figure legends; 7) tables; 8) illustrations and graphics. For 
more information on manuscript format, please refer to the following guidelines. 
1) The Title Page should contain on separate lines author(s) name, institution, and the title of the article. 
In addition it should contain the e-mail and postal addresses, plus telephone and fax numbers of the 
corresponding author. All author affiliations and corresponding authors addresses should be supplied in 
English. 
2) The Abstract of original papers must be structured with the following headings: Purpose, Methods, 
Results, Conclusion, and should not exceed 250 words. Abstracts of review articles, perspective of 
ophthalmology, historical articles, case reports and case series do not have to be structured in this same 
way. Diagnosis/Therapy in Ophthalmology contributions, editorials and Letters to the Editor do not have an 
abstract, please see separate instructions below. Key Words:Four to nine key words for indexing 
purposes must be given. 
3) Main text should be concise and as far as possible free of specialised language, and unnecessary or 
not generally accepted abbreviations. Abbreviations must be spelled out on first mention. 
The following order of presentation is recommended: 
Introduction stating the purpose of the article and key aspects of present knowledge. Extensive literature 
reviews are not desirable. Primary sources are preferred. 
Material: Notice that the journal requests that all research has followed the Tenets of the Declaration of 
Helsinki, and that the details are provided in the manuscript text. Methods of investigation with sufficient 
information to permit repetition of experiments. The journal requires that authors who report on eye cancer 
include in their manuscript the Union for International Cancer Control / American Joint Committee on 
Cancer (UICC / AJCC) Tumor, Node, Metastasis (TNM) categories and stages (7th Edition) in addition to 
any other cancer classification scheme the authors wish to use. 
Statistics and mathematical analyses should be applied when appropriate and be described under 
Methods. Authors are encouraged to take advice from an expert of statistics already when the study is 
designed. The following rules regarding reporting should be adhered to: 
- Report proportions if the number of subjects is smaller than 10 (e.g. 2 of 5), report percentages in 
integers if the number of subjects is less than 100 (e.g. 34%). If the number of subjects is larger, one 
decimal place can be given, but is seldom necessary (e.g. 34.5%). 
- Report summary statistics of normally distributed variables as mean with standard deviation, and other 
variable as medium with range. Use parametric and nonparametric statistical tests accordingly. 
- Give exact p-values (e.g. p=0.15 and p=0.034); if p-value is smaller than 0.0001, report p - Give 95% 
confidence intervals for main findings. 
- Mention the statistical test used with the p-value (e.g. p=0.015, paird t-test). If the same test is repeated, 
it does not need to be specified again. 
- The statistical software used need not be referenced in the manuscript text, unless it is specific for the 
statistical method used (or these can be put later under a separate heading, with a pointer here). 
Results should be as clearly presented as possible. Scatterplots and similar graphical presentations are 
often preferable to tables. Do not duplicate in the text data that is given in tables and figures. 
Discussion should be based directly on the author(s)' contributions and with reference to prior 
investigations, pointing out the significance and the limitations of the study. 
4) Acknowledgements should indicate the name, society and date of the meeting if an abstract of the 
article has been presented previously. Support for the study can also be published here. A statement 
regarding possible conflict of interest must be included here (e.g. disclose financial interest in the 
equipment or method described, research or travelling grant support, consulting services provided, or 
disclose absence of commercial or propriety interest). 
5) References. The author(s) is responsible for accurate references that must conform to journal style. If 
references are not in journal style, the manuscript will be returned for editing without review. References in 
the text should quote the last name(s) of the author(s) and the year of publication: (Brown & Smith 2003) 
or (Brown et al. 2003) when there are three or more authors. The reference list should include only those 
publications cited in the text and must be listed in alphabetic order with no numbering. Initials of forenames 
are placed after the surname with no commas, periods or spaces between initials. All articles should be 
cited in the original language of the reference, not as an English translation. References 'in press' must be 
filled in at latest in at the proof stage. Reference to unpublished material should state the author's name 
followed by 'unpublished' or 'personal communications'; such references should not appear in the 
reference list. Titles of journals are abbreviated according to the recommendations of the Index Medicus. 
We recommend the use of a tool such as Reference Manager for reference management and formatting. 
Reference Manager reference styles can be searched for 
here:http://www.refman.com/support/rmstyles.asp 
Examples of reference list: 
Abrahamsson M, Ohlsson J & Abrahamsson H (2003): Clinical evaluation of an eccentric infrared 
photorefactor; the PowerRefractor. Acta Ophthalmol Scand 81: 605-610. 
Sharaaway T (2003): Glaucoma surgery: Lest we forget. Acta Ophthalmol 81: 553-555. 
Bailey IL (1998): Visual acuity. In: Benjamin WJ (ed.) Borish's Clinical Clinical Refraction. Philadelphia: 
W.B.Saunders 179-202. 
6) Figure Legends. Legends to figures should make the meaning of each illustration understandable 
without reference to the text. Figure legends should be on separate pages. 
7) Tables should be numbered consecutively in Arabic numerals and cited in the text. The approximate 
location in the text should be indicated in the manuscript. Each table should be typed as a separate 
document. Tables should have legends. Footnotes can be used in tables, if necessary. 
8) Illustrations and graphics. All photographs, drawings and graphs are referred to as figures, 
abbreviated Fig., and should be numbered in sequence with Arabic numerals. Photographs and other 
images should be cropped so that only relevant parts of original figures are submitted. All figures should 
be planned to fit the printed column, 56, 117 or 178mm, and non-photographic illustrations should be 
professionally produced using modern software. Authors are encouraged to print their illustrations in the 
intended size before submission to make sure that sizes have been chosen correctly. The authors should 
also adapt graphics for the 3-column format and adjust the font size accordingly. Graphics are not re-
drawn by the publisher. Histograms and similiar graphics should not be 3-dimensional. Complicated 
graphical illustrations can often be made more legible by the use of colour. Figures should be on separate 
pages. Please submit all line graphics as EPS or PDF files and photographs as TIF or PDF files. When 
submitting EPS files please embed fonts when you can. For more information on preparing and submitting 
figures please visit: http://www.blackwellpublishing.com/bauthor/illustration.asp 
Consult the section on colour charges, colour policy and page charges below. 
REVIEW ARTICLES 
Review articles should be arranged in the following order: 1) title page; 2) abstract; 3) key words; 4) text, 5) 
acknowledgement; 6) references; 7) tables; 8) legends to figures; 9) illustrations and graphics. 
Review articles have high priority. They are usually invited, but the journal may also accept unsolicited 
review articles. Articles with clinical relevance are preferred. Manuscripts of this type may be considerably 
longer than other contributions with numerous illustrations and more extensive reference lists. Review 
papers have an abstract that may be in a single segment. 
CASE SERIES and CASE REPORTS 
Case series and case reports should be arranged in the following order: 1) title page; 2) abstract; 3) key 
words; 4) text, 5) acknowledgement; 6) references; 7) tables; 8) legends to figures; 9) illustrations and 
graphics. 
Acta Ophthalmologica receives many more case reports than it can publish. Published case reports should 
provide unquestionably new knowledge, or be exceptionally well documented and educational. Authors 
should check before submission of case reports that their manuscript meets either of these requirements. 
Most manuscripts in this section are rejected without outside review for lack of new content and low 
priority. It is usually preferable to submit rare of unusual case observations in a much condensed format as 
a letter to the editor. Please consult also the Diagnosis/Therapy in Ophthalmology section below. 
LETTERS TO THE EDITOR 
Acta Ophthalmologica will consider letters for publication. Letters to the editor will be published 
electronically in each issue of Acta. Other material, including articles, may also be published in electronic 
issues of Acta and not on paper. The electronic articles and letters will be listed in exactly the same way as 
other material in Acta, including in international databases. They will be accessible in the same way as 
other published material, except in the paper issue of the journal. 
Letters should encourage scientific discussion on topics pertaining to ophthalmology, and may also consist 
of short reports or observations. A letter to the editor should start with 'Editor,' and be short and to the 
point. Long introductions and discussions are unacceptable. Letters should have title page, main text, no 
abstract, no key words, and no subheadings. Letters should not exceed 600 words and should have a 
maximum of 5 references and 1 table or 1 illustrations. It could be panel of figures. The editors reserve the 
right to edit letters for clarity and brevity. 
DIAGNOSIS/THERAPY IN OPHTHALMOLOGY 
The Diagnosis/Therapy in Ophthalmolgy section features photo essays, i.e. short contributions that focus 
on images rather than text. Submissions should be based on images which emphasise features relevant to 
contemporary diagnosis and treatment of eye disease. The aim of this section is to improve patient care by 
alerting readers to appropriate use of diagnostic techniques and important clinical signs. This section in not 
intended for reporting rare or unusual findings unless the technique described has wide applicability. The 
text should have no abstract, no subheadings and should start directly with the case report, followed by a 
short comment. The text should be about two doubly spaced manuscript pages. The legends are typed on 
a separate page. Illustrations can include any combination of clinical photographs, ultrasonographic and 
radiology images, histopathology slides, topographic maps, visual fields and other relevant pictures, 
provided that they have educational value to the general reader and cropped to show only essential 
details. The images must be accompanied by a concise comment and up to five references which put 
them in perspective. Acta will usually only print one article in this section in every issue. Acta has a section 
editor for this type of article. 
THESES 
Acta publishes full-text theses (academic dissertations) online. A one or two-page abstract is published in 
the printed version of the journal, while full text of the theses is available online only. Theses are freely 
available on the web both to subscribers and to non-subscribers. This means that theses can be found on 
Medline and are easily available over the world. The publication cost is low and the service is supported by 
Acta's owners, the Nordic Ophthalmological Societies. Only ophthalmic theses defended at universities in 
the Nordic countries can use this service. Clickhere for further information. 
LANGUAGE 
Papers should be written in English. The spelling should follow the Concise Oxford Dictionary, i.e. British 
English. For medical terms, Dorland's Medical Dictionary should be used. The minus sign should be shown 
as -. In decimal fractions use a full stop and not a comma. Footnotes should be avoided. In abbreviations, 
units, and symbols, standardised terms should be used. 
COLOUR FIGURES AND POLICY 
Acta requests all figures that are inherently in colour (e.g. fundus photographs, clinical photographs, 
histology, optical coherence tomography) be submitted to the journal in true colour. If other figures are 
submitted in colour (photographs or graphics) it is assumed that they are also intended for publication in 
colour. For manuscripts where the formal corresponding authors is a member of the Nordic 
Ophthalmolgocial Societies, a member of EVER, or a personal subscriber, there will be no colour 
reproduction charge. For other manuscripts, a colourwork agreement formmust be completed and 
submitted, authorizing a charge of GBP 300. Please submit colour work forms to: 
Maryam Malek 
Wiley 
1 Fusionopolis Walk, #07-01 
Solaris South Tower 
Singapore 138628 
Fax: +65 6643 8599 
mailto: aos@wiley.com 
 
Invited articles are not charged for colour illustrations. 
PAGE CHARGES 
Any article which exceeds 4 pages will be charged. Excess pages must be paid for at a rate of £80 (UK) 
per page unless specific written arrangements have been negotiated with the Editor-in-Chief. Invited 
papers are as a rule not charged for excess pages. Papers will be invoiced upon publication. One Acta 
page contains about 7,000 letters, space between words included. Please note that page charges apply to 
all authors, including subscribers and authors published in the online only section. 
COPYRIGHT FORM 
If your article is accepted, please sign and return the Copyright Transfer Agreement to Production Editor, 
Maryam Malek, by email aos@wiley.com, by fax +65 6643 8599 or by air-mail as soon as possible. The 
mailing address is: Maryam Malek, Production Editor, Wiley, 1 Fusionopolis Walk, #07-01, Solaris South 
Tower, Singapore 138628 
OPEN ACCESS 
Online Open is available to authors of primary research articles who wish to make their article available to 
non-subscribers on publication, or whose funding agency requires grantees to archive the final version of 
their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee 
to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as 
well as deposited in the funding agency's preferred archive. For more information on Online Open 
including the full list of terms and conditions and the online order form please go to here. 
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your 
paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other 
article. They go through the journal's standard peer-review process and will be accepted or rejected based 
on their own merit. 
 
Please note: 50% discounted OnlineOpen fee for Members of the Danish Ophthalmological Society, the 
Finnish Ophthalmological Society, the Icelandic Ophthalmological Society, the Norwegian 
Ophthalmological Society, the Swedish Ophthalmological Society or the European Association for Vision 
and Eye Research (EVER). 
PROOFS 
Proofs will be sent to one author only. The corresponding author will receive an e-mail alert containing a 
link to a web site. A working e-mail address must therefore be provided for the corresponding author. The 
proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be 
required in order to read this file. This software can be downloaded (free of charge) from the following web 
site: 
http://www.adobe.com/products/acrobat/readstep2.html 
This will enable the file to be opened, read on screen and printed out in order for any corrections to be 
added. Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address 
is available. Any alteration made during linguistic editing by the publisher should be checked carefully and 
the proof returned with the least possible delay and with a minimum of essential corrections. Excessive 
changes made by the author in the proofs, excluding typesetting errors, will be charged separately. If a 
significant amount of new material is added the paper may be re-dated. Second proofs will be sent only if 
specifically and justifiably requested by the author. Final proofs are read by the publisher. 
AUTHOR SERVICES 
Online production tracking is now available for your article through Wiley-Blackwell's Author 
Services 
Author Services enables authors to track their article - once it has been accepted - through the production 
process to publication online and in print. Authors can check the status of their articles online and choose 
to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique 
link that enables them to register and have their article automatically added to the system. Please ensure 
that a complete e-mail address id provided when submitting the manuscript. 
Visit www.authorservices.wiley.com/bauthor/ for more details on online production tracking and a for a 
wealth of resources including FAQs and tips on article preparation, submission and more. 
SUPPLEMENTS 
Monographs of large original work, proceedings of symposia, etc. may be published as supplements, the 
full cost being paid by the author. Examples of material that may be accepted as supplements include 
theses with ophthalmic subjects or meeting proceedings from Nordic ophthalmic societies or ophthalmic 
meetings in the Nordic countries. Supplements are not subject to revision by the Editor. The quality of the 
language must meet the standards maintained by the journal, and all the above-mentioned instructions 
should be followed. All costs for production, postage to the subscribers, and translation or linguistic 
revision must be paid by the author. Supplements are sent free of charge to the subscribers. It is the policy 
to acknowledge in supplements any major sponsorship. 
OFFPRINTS 
There are no free offprints. Information on how to order offprints and reprints will accompany the proofs. 
To order offprints please visit http://www.blackwellpublishing.com/bauthor/offprint.asp or 
email offprint@cosprinters.com. 
AUTHOR MATERIAL ARCHIVE POLICY 
Please note that unless specifically requested, Wiley-Blackwell will dispose of all hardcopy or electronic 
material submitted two months after publication. If you require the return of any material submitted, please 
inform the editorial office or production editor as soon as possible if you have not already done so. 
PAPER 
The publisher's policy is to use permanent paper from mills that operate a sustainable forestry policy, and 
which have been manufactured from pulp which is processed using acid-free and elementary chlorine-free 
practices. Furthermore, the publisher ensures that the text paper and cover board used has met 
acceptable environmental accreditation standards. 
DISCLAIMER 
The Publisher, the Nordic Ophthalmological Societies or Editors cannot be held responsible for errors or 
any consequences arising from the use of information contained in this journal; the views and opinions 
expressed do not necessarily reflect those of the Publisher, the Nordic Ophthalmological Societies or 
Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, the 
Nordic Ophthalmological Societies or Editors of the products advertised. 
EDITORIAL OFFICE 
Professor Einar Stefánsson 
University of Iceland 
National University Hospital 
Department of Ophthalmology 
101 Reykjavík, Iceland 
Bryndis Thordardottir 
Editorial Manager 
Tel: +354 897 9752 
Fax: +354 543 4831 
E-mail: actaophthalmologica@hi.is 
 
 
 
 
  
 
 
Parecer da Comissão de Ética para a Saúde 




